BD and Suttons Creek, a BlueRidge Life Sciences company, announced a strategic, non‑exclusive partnership on April 27, 2026, to help pharmaceutical and biotech firms develop biologics and GLP‑1 therapies more efficiently.
The collaboration brings together BD’s ZebraSci, a device‑agnostic combination product testing organization, with Suttons Creek’s end‑to‑end combination product development services. Together they will provide objective, data‑driven testing and integrated development support to reduce risk, shorten timelines and improve regulatory outcomes for complex drug‑device products.
By combining testing expertise with development and regulatory guidance, the partnership aims to streamline the engineering, testing, quality and regulatory pathways that are often fragmented for combination products. The move expands BD’s service portfolio and positions the company to capture a larger share of the growing biologics and GLP‑1 combination product market, offering a moderate benefit to its long‑term growth prospects.
BD’s Worldwide President of Pharmaceutical Systems, Patrick Jeukenne, said the collaboration “brings together complementary expertise from both companies, helping customers reduce development risk and address regulatory considerations while maintaining choice and flexibility in how they move their programs forward.” Suttons Creek’s Vice President of Solutions Engineering, Carolyn Dorgan, added that the partnership “enables a more coordinated and efficient path forward” by addressing fragmentation that often drives FDA data requests.
The partnership aligns with BD’s broader strategic transformation, which includes a planned spin‑off of its Biosciences and Diagnostic Solutions business with Waters Corporation. By strengthening its remaining core businesses, BD seeks to accelerate growth in high‑margin biologic drug delivery platforms while leveraging the expanding GLP‑1 market, projected to reach $190 billion by 2035.
Suttons Creek, part of BlueRidge Life Sciences, has supported over 120 drug and biologic delivery devices for more than 70 clients, bringing deep expertise in bridging pharmaceutical and device complexities. The combined capabilities are expected to provide a comprehensive solution to clients navigating the regulatory and technical challenges of combination products.
While the announcement does not include specific financial projections, the partnership is expected to enhance BD’s service revenue mix and support its long‑term growth strategy by tapping into a high‑growth segment that complements its existing biologics and drug delivery businesses.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.